The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

Patients on the firm's SSTR-targeted radiopharmaceutical had improved progression-free survival compared to patients on an mTor inhibitor in a Phase III trial.

The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.

NEW YORK – By the end of a controversial workshop Thursday on whether to test patients for genetic abnormalities that put them at risk of severe chemotherapy-related toxicities, oncologists seemed ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.